Man Group PLC Beam Therapeutics Inc. Transaction History

Man Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$23.01 - $32.46 $1.22 Million - $1.71 Million	-52,827 Reduced 80.11%	13,117 $315,000
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $1.64 Million - $2.01 Million	55,980 Added 561.82%	65,944 $2.11 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $300,414 - $486,143	9,964 New	9,964 $305,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $2.44 Million - $5.09 Million	81,611 Added 697.65%	93,309 $3.61 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $628,533 - $961,107	11,698 New	11,698 $670,000
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $439,734 - $882,693	-6,858 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $296,025 - $501,474	4,153 Added 153.53%	6,858 $549,000
Q4 2020 Feb 16, 2021	BUY	$22.24 - $95.63 $60,159 - $258,679	2,705 New	2,705 $220,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.